达比加群酯联合氯吡格雷治疗非瓣膜性房颤患者的抗凝效果和安全性分析

Analysis of Anticoagulant Efficacy and Safety of dabigatran combined with clopidogrel in treatment of NVAF

目的探究达比加群酯联合氯吡格雷治疗非瓣膜性房颤的抗凝效果和安全性。方法选取2015年1月-2017年12月间某院的非瓣膜性房颤住院患者292例,随机分为对照组和联合用药组,每组146例,比较两组的凝血功能指标PT、APTT、TT、INR和不良反应发生情况。结果治疗3个月后,对照组和联合用药组患者的凝血功能获得了明显改善,联合用药组的指标改善情况比对照组更好,两组比较差异具有统计学意义(P<0.05)。结论达比加群酯联合氯吡格雷对非瓣膜性房颤患者具有较好的抗凝效果,具有一定的临床推广应用价值。

Objective To analysis of anticoagulant efficacy and safety of dabigatran combined with clopidogrel in treatment of NVAF. Methods Patients（ 292 cases） with NVAF in A hospital from Jan. 2015 to Dec. 2017 were randomly divided into control（ 146 cases） and drug combination（ 146 cases） groups,and the PT,APTT,TT,INR score and adverse reaction in two groups were compared. Results The NVAF patients in two groups were treated for 3 month. The coagulation function of control and drug combination groups was obtained obvious improvement. The coagulation function of drug combination groups was better than control groups,and there was difference between two groups（ 〈0. 05）. Conclusion Dabigatran combined with clopidogrel has better anticoagulant efficacy in treatment of NVAF,which has a certain clinical application value.